» Articles » PMID: 23277402

Role of DNA Repair and Cell Cycle Control Genes in Ovarian Cancer Susceptibility

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2013 Jan 2
PMID 23277402
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have identified several single nucleotide polymorphisms (SNPs) in the population that are associated with variations in the risks of many different cancer diseases. For ovarian cancer, the known highly penetrant susceptibility genes (BRCA1 and BRCA2) are probably responsible for only 40% of the excess familial ovarian cancer risks, suggesting that other susceptibility genes of lower penetrance exist. The aim of the present study was to evaluate the role of SNPs in three genes, XRCC2 (R188H), ERCC2 (K751Q) and CDKN1B (V109G) which are with moderate risk for ovarian cancer susceptibility in Egyptian women. We further investigated the potential combined effect of these genes variants on ovarian cancer risk. The three genes polymorphisms were characterized in 100 ovarian cancer Egyptian females and 100 healthy women by (RFLP-PCR) method in a case control study. Our results revealed that the frequencies of AC genotypes of ERCC2 (K751Q), and GG genotypes of CDKN1B (V109G) polymorphisms were significantly higher in EOC patients than in normal individual (P = 0.007, 0.02 respectively). The frequencies of AA genotype of XRCC2 (R188H) and CC genotype of ERCC2 (K751Q) were higher in EOC patients than in normal individual but without significance (P = 0.06, 0.38 respectively). Also, no association between any one of the three studied genes polymorphisms and the clinical characteristics of disease. The combination of GA (XRCC2) + AC (ERCC2) + GG (CDKN1B) was significantly associated with increased EOC risk. Also, the combination for GA (XRCC2) + AC (ERCC2) and the combination of AA (XRCC2) + CC (ERCC2) were significantly associated with increased EOC risk. There was significant difference in CA125 values between EOC and control Group (P < 0.001). Our results suggested that, XRCC2, ERCC2 and CDKN1B genes are important candidate genes for susceptibility to EOC. Also, gene-gene interaction between GA (XRCC2) + AC (ERCC2) + GG (CDKN1B) polymorphism may be associated with increased risk of EOCC in Egyptian women.

Citing Articles

The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.

Hu J, Xu Z, Ye Z, Li J, Hao Z, Wang Y Cancer Med. 2022; 12(1):541-556.

PMID: 35637613 PMC: 9844622. DOI: 10.1002/cam4.4891.


Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk.

Yuan C, Liu X, Li R, Yan S, Kong B Arch Med Sci. 2020; 16(3):682-691.

PMID: 32399118 PMC: 7212224. DOI: 10.5114/aoms.2020.94657.


Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype.

Chasseloup F, Pankratz N, Lane J, Faucz F, Keil M, Chittiboina P J Clin Endocrinol Metab. 2020; 105(6).

PMID: 32232325 PMC: 7190031. DOI: 10.1210/clinem/dgaa160.


-V109G Polymorphism Is Not Associated with the Risk of Prostate Cancer: A Case-Control Study of Han Chinese Men in Central China.

Zhang M, Liang Q, Zhang L, Hao Z, Zhou J, Zhang L Dis Markers. 2018; 2018:1418609.

PMID: 29750086 PMC: 5884233. DOI: 10.1155/2018/1418609.


Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.

Kamali M, Hamadani S, Neamatzadeh H, Mazaheri M, Shehneh M, Modaress Gilani M Asian Pac J Cancer Prev. 2017; 18(7):1743-1749.

PMID: 28749098 PMC: 5648374. DOI: 10.22034/APJCP.2017.18.7.1743.


References
1.
Song H, Ramus S, Shadforth D, Quaye L, Kjaer S, Dicioccio R . Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res. 2006; 66(20):10220-6. DOI: 10.1158/0008-5472.CAN-06-2222. View

2.
Pharoah P, Antoniou A, Bobrow M, Zimmern R, Easton D, Ponder B . Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002; 31(1):33-6. DOI: 10.1038/ng853. View

3.
Sutherland R, Musgrove E . Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004; 9(1):95-104. DOI: 10.1023/B:JOMG.0000023591.45568.77. View

4.
Berwick M, Vineis P . Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst. 2000; 92(11):874-97. DOI: 10.1093/jnci/92.11.874. View

5.
Parshad R, Price F, Bohr V, Cowans K, Zujewski J, SANFORD K . Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer. 1996; 74(1):1-5. PMC: 2074608. DOI: 10.1038/bjc.1996.307. View